About Alumis
Alumis is a company based in San Francisco (United States) founded in 2003. Alumis has raised $529 million across 5 funding rounds from investors including General Atlantic, Piper Sandler and HBM Healthcare Investments. The company has 168 employees as of December 31, 2024. Alumis operates in a competitive market with competitors including Moderna, Forge Biologics, Aclaris Therapeutics, Annexon and Ventyx Biosciences, among others.
- Headquarter San Francisco, United States
- Employees 168 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alumis Inc.
-
Annual Revenue
Not available
-
Net Profit
-$294.23 M (USD)-89.84as on Dec 31, 2024
-
EBITDA
-$297.6 M (USD)-89.69as on Dec 31, 2024
-
Total Equity Funding
$529 M (USD)
in 5 rounds
-
Latest Funding Round
$40 M (USD), Post-IPO
Jul 17, 2024
-
Investors
General Atlantic
& 13 more
-
Employee Count
168
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Alumis
Alumis is a publicly listed company on the NASDAQ with ticker symbol ALMS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Alumis
Unlock access to complete
Leadership Team
31 people
Software Development Team
9 people
Product Management Team
8 people
Operations Team
3 people
Finance and Accounting
3 people
Data Analysis and Operations Team
3 people
Sr. Team
2 people
Scientist Team
2 people
Unlock access to complete
Funding Insights of Alumis
Alumis has successfully raised a total of $529M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alumis
Alumis has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include General Atlantic, Piper Sandler and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked | |
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Locked | Locked | Locked |
Investor details for Alumis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alumis
Investment portfolio details for Alumis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alumis
Detailed financials for Alumis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alumis Comparisons
Peer comparison for Alumis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alumis
Alumis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Forge Biologics, Aclaris Therapeutics, Annexon and Ventyx Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by the company.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
Detailed competitors of Alumis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alumis
Complete news archive for Alumis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alumis
Alumis was founded in 2003 and raised its 1st funding round 18 years after it was founded.
Alumis is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Martin Babler is the current CEO of Alumis.
Alumis is a funded company, having raised a total of $529M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Alumis is 168.
Alumis was founded in 2003 and is based in San Francisco, United States. Focus is placed on the development of therapeutics targeting autoimmune diseases within the biotechnology sector. Operations involve research into inhibitors like the lead candidate SK-001, a TYK2 pseudokinase allosteric inhibitor for psoriasis. The TYK2 gene is recognized for encoding a tyrosine kinase that mediates inflammation and autoimmune responses.
Alumis's top competitors include Moderna, Forge Biologics and Annexon.
Yes, Alumis is publicly traded on NASDAQ under the ticker symbol ALMS.
Alumis has 14 investors. Key investors include General Atlantic, Piper Sandler, HBM Healthcare Investments, AyurMaya, and Foresite Capital.
The ticker symbol of Alumis is ALMS on NASDAQ.